Phase 2/3 clinical study of HP-3150 in patients with cancer pain.
Phase 2
- Conditions
- Cancer pain
- Registration Number
- JPRN-jRCT2080222905
- Lead Sponsor
- Hisamitsu Pharmaceutical Co., Inc
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients confirmed to have various types of cancer who were informed about their disease.
Exclusion Criteria
- Patients with abnormalities at the planned application site.
- Patients with a serious hematologic disorder, hepatic dysfunction, renal dysfunction, hypertension, or heart failure.
- Patients who have undergone an operation or nerve block, etc. that may affect assessment of pain.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method